Company Filing History:
Years Active: 2017
Title: Mei Ono - Innovator in Anti-Tumor Antibody Research
Introduction
Mei Ono is a prominent inventor based in Kanagawa, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of anti-tumor antibodies. Her innovative work has the potential to impact cancer treatment and improve patient outcomes.
Latest Patents
Mei Ono holds a patent for an "Anti-DDR1 antibody having anti-tumor activity." This patent highlights her research on producing anti-DDR1 antibodies and their extensive studies on antitumor activity. The antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 exhibit potent activity, even when used alone, compared to antibodies that bind to other domains. The antibodies demonstrate several activities, including the suppression of cell proliferation, inhibition of cell migration, and reduction of DDR1 and TGF-β expression levels in cells.
Career Highlights
Mei Ono is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. Her work at the company has allowed her to focus on groundbreaking research in antibody development. With her expertise, she has contributed to advancing therapeutic options for cancer patients.
Collaborations
Mei Ono collaborates with notable colleagues, including Yuji Sano and Tsukasa Suzuki. Their combined efforts in research and development have fostered a collaborative environment that enhances innovation in their field.
Conclusion
Mei Ono's contributions to the development of anti-tumor antibodies represent a significant advancement in cancer research. Her innovative work continues to pave the way for new therapeutic strategies that could benefit many patients in the future.